- Last edited on February 7, 2022
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
cl:psychiatric-side-effects-of-medications [on February 7, 2022] psychdb [Offending Agents] |
cl:psychiatric-side-effects-of-medications [on February 7, 2022] psychdb [Depression] |
||
|---|---|---|---|
| Line 6: | Line 6: | ||
| ===== Offending Agents ===== | ===== Offending Agents ===== | ||
| * Individuals may experience changes in mood, cognition, memory, or behaviour during glucocorticoid treatment or withdrawal.[([[https://www.ncbi.nlm.nih.gov/pubmed/25272344|Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., ... & Joëls, M. (2014). Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. American Journal of Psychiatry, 171(10), 1045-1051.]])] | * Individuals may experience changes in mood, cognition, memory, or behaviour during glucocorticoid treatment or withdrawal.[([[https://www.ncbi.nlm.nih.gov/pubmed/25272344|Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., ... & Joëls, M. (2014). Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. American Journal of Psychiatry, 171(10), 1045-1051.]])] | ||
| - | * Severe neuropsychiatric sequelae including suicide, suicide attempts, psychosis, mania, depression, panic disorder, delirium, confusion, and disorientation have also been reported. | + | * Severe neuropsychiatric sequelae including suicide, suicide attempts, psychosis, mania, depression, panic disorder, delirium, confusion, and disorientation have also been reported.[([[https://www.ncbi.nlm.nih.gov/pubmed/25272344|Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., ... & Joëls, M. (2014). Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. American Journal of Psychiatry, 171(10), 1045-1051.]])] |
| ===== Cognition ===== | ===== Cognition ===== | ||
| The diagnosis for a **Substance/Medication-Induced Major or Mild Neurocognitive Disorder** is as follows: | The diagnosis for a **Substance/Medication-Induced Major or Mild Neurocognitive Disorder** is as follows: | ||
| Line 50: | Line 50: | ||
| ===== Depression ===== | ===== Depression ===== | ||
| - | <alert type="info" icon="fa fa-book fa-lg fa-fw"> | ||
| - | See also: | ||
| - | * **[[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181628/|Tango, R. C. (2003). Psychiatric side effects of medications prescribed in internal medicine. Dialogues in clinical neuroscience, 5(2), 155.]]** | ||
| - | * **[[https://jamanetwork.com/journals/jama/fullarticle/2684607|Qato, D. M., Ozenberger, K., & Olfson, M. (2018). Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States. JAMA, 319(22), 2289-2298.]]** | ||
| - | </alert> | ||
| - | |||
| <alert icon="fa fa-arrow-circle-right fa-lg fa-fw" type="success"> | <alert icon="fa fa-arrow-circle-right fa-lg fa-fw" type="success"> | ||
| See main article: **[[mood:substance-medication|]]** | See main article: **[[mood:substance-medication|]]** | ||